Jax DiEugenio

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

BB-1701 generated responses with manageable safety in HER2-expressing breast cancer previously treated with an ADC with a topoisomerase I inhibitor.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

In BRUIN CLL-314, pirtobrutinib met the primary end point of noninferior ORR vs ibrutinib in both the ITT and pretreated subsets of patients with CLL/SLL.

John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

The CHMP has issued a positive opinion for the use of vorasidenib in IDH1/IDH2-mutant grade 2 glioma

VS-7375 earned FDA fast track designation for KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The European Commission and Health Canada have approved belantamab mafodotin-based combinations for relapsed/refractory multiple myeloma.

Tabelecleucel earned FDA priority review for EBV-positive post-transplant lymphoproliferative disease following a January 2025 complete response letter.

R. Lor Randall, MD, FACS, discusses when to intervene prophylactically in patients with advanced cancer and skeletal metastases.

Jue Wang, MD, discusses persistent gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.

Mirdametinib received conditional EU approval for treating NF1-associated plexiform neurofibromas in patients 2 years of age and older.

Darolutamide receives EU approval with ADT for metastatic hormone-sensitive prostate cancer.

Cathy Eng, MD, FACP, FASCO, discusses real-world data on KRAS G12C–mutated mCRC, highlighting its potential prognostic impact in the frontline setting.

Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.

The FDA has granted priority review to TAR-200 for BCG-unresponsive, high-risk NMIBC with CIS, with or without papillary tumors.

Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Real-world analysis showed ctDNA positivity was associated with higher recurrence risk and reduced overall survival in early breast cancer.

Rocío García-Carbonero, MD, PhD, discusses findings from a subgroup analysis of FRESCO-2 with fruquintinib in refractory mCRC.

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.